All In Biotech

Free tool

FAERS Monitor: Epclusa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214187 or its brand name (Epclusa, Sofosbuvir, Velpatasvir). Reports on generic versions are filed under their own applications.

Reports

12,567

Serious

3,745

30% of reports

Hospitalization

1,368

Death reported

566

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue2,600
  • headache2,201
  • nausea1,163
  • diarrhoea650
  • drug ineffective549
  • insomnia508
  • hepatitis c410
  • treatment failure334
  • vomiting324
  • death291
  • dizziness282
  • rash255
  • product dose omission issue246
  • abdominal discomfort234
  • intentional dose omission215

Reports by year received

View as table
YearReports
2016400
20172,137
20182,222
20192,661
20201,692
20211,021
2022934
2023540
2024407
2025345
2026208

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,592 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis cSignal41058.853.422,462
intentional dose omissionSignal21512.711.12,293
treatment failureSignal3346.86.11,637
headacheSignal2,2015.95.79,179
fatigueSignal2,6005.65.410,175
insomniaSignal5083.22.9773
nauseaSignal1,1632.52.31,046
abdominal discomfortSignal2342.32.1179
diarrhoea6501.71.6186
product dose omission issue2461.41.228
vomiting3241.21.07
rash2551.00.90
dizziness2820.90.81
drug ineffective5490.70.677
death2910.60.5101

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.